2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, White Blood Cell Disorders, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

2254 Patient-reported health-related quality of life with alternative elranatamab dosing strategies in relapsed/refractory multiple myeloma: Exploratory analyses from MagnetisMM-9

Matthew J. Pianko, MD, Mohamad Mohty, MD, PhD2, Nizar Bahlis, MD3, Ajay K Nooka, MD, MPH4, Scarlette Kienzle5, Aster Meche, PhD6, Didem Aydin, MD, PhD7, Parnian Eghbalian8, Fraence Hardtstock9, Mohammed Ashraf Chaudhary10, Marco Dibonaventura, PhD11, Charlotte Pawlyn, M.D., Ph.D.12
1 Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States
2 Department of Hematology, Hôpital Saint-Antoine, INSERM UMRs938, Sorbonne University, Paris, France
3 Department of Oncology, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada
4 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
5 Cytel Inc., Berlin, Germany
6 Pfizer Inc, Cambridge, MA, United States
7 Pfizer Inc., Istanbul, Turkey
8 Cytel Inc., Berlin, Germany
9 Cytel Inc., Berlin, Germany
10 Pfizer Inc, Collegeville, Pennsylvania, United States
11 Pfizer Inc, Cambridge, MA, United States
12 The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom

Background

Elranatamab is a BCMA×CD3 bispecific antibody approved for the treatment of relapsed/refractory multiple myeloma (RRMM). Per labeling, elranatamab is administered as 2 step-up doses (12 and 32 mg on Day [D] 1 and D4), followed by QW (once weekly) administration through Week 24. The open-label phase 1/2 study (MagnetisMM-9; NCT05014412) evaluated alternative elranatamab dosing strategies, including a response-adapted regimen (Part 1) and a higher-dose extended-interval regimen (Part 2B). Patients who achieved a partial response (PR) or better for 2 months could transition to Q2W (every 2 weeks), and those who maintained their response could transition to Q4W (every 4 weeks) dosing at Week 49. This exploratory analysis evaluated health-related quality of life (HRQoL) associated with these alternative dosing strategies using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30).

Methods

MagnetisMM-9 included triple-class refractory patients with RRMM with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. An exploratory descriptive analysis was conducted among patients enrolled in Part 1 or Part 2B who completed a baseline and at least one follow-up QLQ-C30 assessment. In both parts, patients received priming doses of 4 mg and 20 mg on D1 and D4, respectively. In Part 1, patients began QW (76 mg) dosing, switched to Q2W (76 mg) after achieving a PR or better for 2 months, and then switched to Q4W (116 or 152 mg) at Cycle (C) 7. In Part 2B, patients started at QW (76 mg) dosing during C1, switched to Q2W (116 or 152 mg) at C2, and switched to Q4W (116 or 152 mg) at C7. QLQ-C30 scores were standardized to a 0–100 scale; higher scores indicate better functioning/HRQoL status on the functional scales and the Global Health Status scale, and greater symptom burden on the symptom scales. Observed mean scores and mean changes from baseline were summarized descriptively by visit. In responder analyses, patients were classified as stable (<10-point change from baseline), improved (≥10-point change), or deteriorated (≥10-point change in the opposite direction).

Results

Sixty-two patients were included (Part 1, n=33; Part 2B, n=29). Mean age at baseline was 60.6 years in Part 1 and 65.1 years in Part 2B, with 42.4% and 48.3% male patients, respectively. QLQ-C30 completion rates remained high throughout follow-up despite decreasing patient numbers, with 85.7% of evaluable patients completing the assessment at Year 1 (C12; Part 1, n=15; Part 2B, n=9).

Baseline QLQ-C30 scores were broadly comparable between Part 1 and Part 2B across Global Health Status/Quality of Life (QoL) (66.7 vs 62.2), Physical Functioning (84.2 vs 78.7), Role Functioning (77.1 vs 76.3), Emotional Functioning (83.6 vs 84.0), and Cognitive Functioning (84.4 vs 85.9). However, baseline Social Functioning was higher in Part 1 (80.7 vs 68.0). Baseline symptom scores were also generally similar across most domains, including Pain (28.1 vs 32.1) and Fatigue (27.4 vs 32.5), whereas Financial Difficulties scores were higher in Part 2B (9.4 vs 25.6).

At Year 1, mean change from baseline (95% CI) in Global Health Status/QoL was −2.2 [−13.2 to 8.7] points in Part 1 and −5.6 [−19.1 to 8.0] points in Part 2B. Mean changes in Physical Functioning (−2.7 [−7.3 to 1.9] vs −4.4 [−12.9 to 4.1]) and Fatigue (3.7 [−5.5 to 12.9] vs 2.5 [−11.6 to 16.5]) were similar between groups. Numerically more favorable mean changes from baseline were observed in Part 2B than in Part 1 for Role Functioning (−7.8 [−16.2 to 0.7] vs 3.7 [−2.0 to 9.4]) and Pain (2.2 [−10.8 to 15.2] vs −9.3 [−18.6 to 0.05]).

In responder analyses, most patients were classified as stable across most QLQ-C30 domains at Year 1, including Global Health Status/QoL (53.3% vs 66.7%). Improvement rates for Social Functioning (33.3% vs 66.7%) and Pain (13.3% vs 55.6%) were numerically higher in Part 2B than in Part 1.

Conclusions
Both alternative elranatamab dosing strategies were associated with maintenance of HRQoL over time, further supporting the evaluation of extended dosing intervals in patients with RRMM treated with elranatamab. The higher-dose extended-interval regimen of Part 2B showed maintained patient-reported functioning and symptom burden, with numerically favorable responder profiles across selected QLQ-C30 domains, although small sample sizes limit interpretation.

Matthew J. Pianko, MD: Pfizer Inc. - Honoraria; Johnson & Johnson - Honoraria; GlaxoSmithKline - Honoraria; Johnson & Johnson - Research Funding; C4 Therapeutics - Research Funding; Pfizer Inc. - Research Funding; CellCentric - Research Funding; AstraZeneca - Research Funding; Regeneron - Research Funding; Bristol Myers Squibb/Celgene - Research Funding; Abbvie - Research Funding; Sanofi-Aventis - Research Funding; Johnson & Johnson - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); GlaxoSmithKline - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony); Pfizer Inc. - Consultancy (Includes expert testimony)